Induced pluripotent stem cells (iPSCs) harboring patient derived SAMD9 mutation offer a unique platform to study the multi-organ involvement observed in this rare disease, referred to as myelodysplasia, infections, restriction of growth, adrenal hypoplasia, genital phenotypes, and enteropathy (MIRAGE) syndrome. The pluripotent nature of iPSCs allows in vitro differentiation into various somatic cell types representing multiple organ systems affected in SAMD9-mutated patients. Hence, in this paper, we present a CRISPR/Cas9-engineered iPSC model carrying SAMD9 c.2948T>G, p.I983S mutation previously reported in two patients with severe MIRAGE syndrome.
Keyphrases
- induced pluripotent stem cells
- crispr cas
- genome editing
- end stage renal disease
- newly diagnosed
- ejection fraction
- early onset
- chronic kidney disease
- single cell
- peritoneal dialysis
- prognostic factors
- case report
- cell therapy
- endothelial cells
- stem cells
- copy number
- patient reported outcomes
- mesenchymal stem cells
- high throughput